Search

The presence of a balance between the production and outflow of intraocular fluid ensures stability of the level of intraocular pressure (IOP). To reduce IOP means to affect one of these variables. For many decades, transscleral technologies in the treatment of glaucoma were considered exclusively as traumatic cyclodestructive interventions that only affect the reduction of intraocular pressure (IOP). These methods have recently been considered as possible ways to influence uveoscleral outflow. This became possible due to the appearance of new lasers, the development of new modes of their operation, points of application in the projection of the pars plana of the ciliary body (for example, TRANS-scleral CFC in micro-pulse mode at λ = 810 µm and CFC using pulsed periodic laser radiation at λ = 1.56 µm). They have a gentler effect and, accordingly, cause fewer side effects and undesirable effects. This explains the increasing shift towards the use of transscleral technologies in the earlier stages of glaucoma, not only for end-stage painful glaucoma resistant to conventional treatment (so-called “last resort surgery”).

Cancer remains one of the leading causes of death. Conventional treatment methods, including radiation and chemotherapy, have limited effectiveness. Therefore, the development of novel approaches to cancer treatment is an urgent challenge. Biomedical cell products (BMCPs) which include adoptive cell therapy (ACT) and dendritic cells vaccines (DCVs) are considered a promising area of research. The aim of the study was to review current ideas about the principles of BMCP therapy, as well as clinical experience with cell-based products used for cancer treatment. The paper summarises the results of clinical use of tumor-infiltrating lymphocytes (TIL-therapy), genetically modified T-cells that express tumour antigen-specific receptors (TCR/CAR T-therapy), as well as DCVs. The use of human immune cells genetically modified ex vivo is a novel and promising approach to cancer treatment. The main analysed ACT approaches which are based on the use of genetically modified T-lymphocytes have some benefits and drawbacks. The paper discusses the methods of BMCP production, provides data on the effectiveness of ACT and DCVs. It pays special attention to safety concerns associated with each treatment method, as well as to other factors limiting their clinical use. It is expected that the main areas of further research will be aimed at increasing BMCP efficacy and reducing adverse reactions.

The objective of this research was studying the state of newborns born to mothers with various risk factors for hypertensive disorders in dependence of the method of prevention of this pathology. The state of 130 newborns of mothers with risk factors who received various methods of preeclampsia prevention during the gestation was analyzed. In the groups of comparison, pregnancy outcomes, incidence and structure of hypertensive disorders, timing and modes of delivery, as well as the morbidity and mortality rates of newborns, depending on the method of preventive therapy of hypertensive disorders were studied. The Pearson criterion χ2 was used to evaluate the relation between qualitative characteristics. The study found that conventional prevention almost halves the development of hypertensive disorders (p

It is revealed, that significant disturbances of cellular and humoral immunity are observed in patients with complicated course of appendicitis. Intramuscular administration of Thimalin (10 mg per injection), Epitalamin (10 mg per injection) for 10 days or Vilon (10 mkg per injection) during 5 or 10 days, applied as a complement to conventional treatment, proved to exert immunostimulatory effects. Moreover, it promoted healing of surgical wounds by a primary tension, and also reduced terms of the treatment by a mean of 5-6 days. To achieve similar medical effects, a twofold lesser number of Vilon single doses is required, than those of Thimalin and Epitalamin. (Med. Immunol., 2008, vol. 10, N 4-5, pp 455-462) .